Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
DEA proposes temporary Schedule I placement for 7-hydroxymitragynine above a specified threshold, making it illegal to possess, handle, or dispense without DEA registration.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies that sell or dispense kratom products containing 7-hydroxymitragynine above the threshold. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date of the temporary order (typically 30 days after publication in Federal Register).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
7-hydroxymitragynine above a specified threshold will be temporarily placed in Schedule I, making it a controlled substance with no accepted medical use and high abuse potential.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies that sell or dispense kratom products containing 7-hydroxymitragynine above the threshold.
What you must do
Identify and immediately cease dispensing or selling any products containing 7-hydroxymitragynine above the threshold; secure and properly dispose of existing inventory per DEA guidelines; ensure no new orders are placed.
Deadline
Effective date of the temporary order (typically 30 days after publication in Federal Register).
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order